Physician profile
Jacques M Schmid
NPI 1972500858
$2,175.07
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $143 · 2021: $324 · 2022: $576 · 2023: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $318.10 | 2019-2023 | Xifaxan, Trulance |
| Pfizer INC. | $310.42 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $294.09 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $197.32 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $165.89 | 2019-2023 | Mounjaro, Jardiance |
| Amarin Pharma, INC. | $143.58 | 2019-2022 | |
| Abbvie INC. | $140.71 | 2021-2023 | Vraylar |
| Sanofi Pasteur INC. | $135.57 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $101.89 | 2019-2023 | Dificid, Delstrigo, Pifeltro |
| Novo Nordisk INC | $73.01 | 2021-2022 | |
| Allergan, INC. | $56.92 | 2019-2020 | |
| Exact Sciences Corporation | $39.38 | 2023 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $38.40 | 2022 | |
| Astellas Pharma US INC | $29.11 | 2023 | Veozah |
| Bausch Health US, LLC | $27.44 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $20.84 | 2023 | Simponi Aria, Simponi, Stelara |
| Amgen INC. | $19.94 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.86 | 2019 | |
| Althera Pharmaceuticals LLC | $16.93 | 2021 | |
| Incyte Corporation | $16.22 | 2022 | |
| Seqirus USA INC | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacques Schmid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.